Skip to content
Health
Link copied to clipboard
Link copied to clipboard

A Jim Wilson start-up will conduct the first FDA-approved tests of a form of gene editing in infants

The start-up from University of Pennsylvania scientist Jim Wilson raised $65 million in late 2022 to help develop the treatment and conduct clinical trials.

A company developing treatments based on research by Jim Wilson, director of the University of Pennsylvania's gene therapy program, has received FDA approval to test a gene therapy in babies for a rare liver disease.
A company developing treatments based on research by Jim Wilson, director of the University of Pennsylvania's gene therapy program, has received FDA approval to test a gene therapy in babies for a rare liver disease.Read moreDaniel Burke Photography